RTP Mobile Logo
Lung Cancer Tumor Board: Clinical Investigators Provide Perspectives on Current Cases and Key Publications in Non-Small Cell Lung Cancer
Released August 2014

Audio proceedings of a live educational activity held adjunct to the 2014 ASCO Annual Meeting on controversial issues in the management of lung cancer featuring the perspectives of Drs Roy S Herbst, John V Heymach, Alice Shaw, Mark A Socinski and Jean-Charles Soria. (Audio Content)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    OVERVIEW OF ACTIVITY
    Lung cancer is a devastating disease with a broad-reaching impact on public health, accounting for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. Development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The advent of these next-generation targeted treatments presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms. Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making lung cancer management decisions in the face of this dynamic clinical environment, but despite the existence of these tools, many areas of controversy persist within academic and community settings. This program uses a review of recent relevant publications and other relevant presentations, ongoing clinical trials, actual patient case discussions and Q&A to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies, including referral of appropriate patients to ongoing pivotal clinical trials.

    LEARNING OBJECTIVES

    • Develop an evidence-based strategy for the systemic treatment of localized NSCLC.
    • Apply the results of emerging clinical research to the multimodality management of Stage III NSCLC.
    • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the treatment of NSCLC.
    • Communicate the efficacy and safety of crizotinib and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK and ROS1 mutation testing.
    • Devise an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced pan-wild-type NSCLC.
    • Describe emerging data on the efficacy and safety of immunotherapy directed at the PD-1/PD-L1 pathway in lung cancer, and consider this information when counseling patients regarding clinical trial participation.
    • Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data and ongoing trials with experimental agents exploiting these targets.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. The participant should review the CME information, listen to the audio MP3s and review the slide presentations.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr HerbstConsulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Merck; Contracted Research: GlaxoSmithKline; Data and Safety Monitoring Board: Pfizer Inc. Dr HeymachAdvisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Synta Pharmaceuticals Corp; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline. Dr ShawAdvisory Committee: ARIAD Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc; Consulting Agreements: ARIAD Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: Pfizer Inc. Dr SocinskiContracted Research: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Merrimack Pharmaceuticals, Onyx Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board: Millennium: The Takeda Oncology Company; Speakers Bureau: Celgene Corporation, Genentech BioOncology. Prof SoriaConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, EMD Serono Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader (Optional)
    Sound card and speakers for audio

    Last review date: August 2014
    Expiration date: August 2015

    This was an independent, accredited educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.

Acknowledge and close

Listen to audio:
Lung Cancer Tumor Board: Clinical Investigators Provide Perspectives on Current Cases and Key Publications in Non-Small Cell Lung Cancer
Released August 2014

Audio proceedings of a live educational activity held adjunct to the 2014 ASCO Annual Meeting on controversial issues in the management of lung cancer featuring the perspectives of Drs Roy S Herbst, John V Heymach, Alice Shaw, Mark A Socinski and Jean-Charles Soria. (Audio Content)

Read print: